GCAN Greater Cannabis Company Inc (PK)

GammaCan International (OTCBB: GCAN) today announced the appointment of Richard Spritz, M.D. to the Company's Scientific Advisory Board. Bringing over thirty years of medical and scientific acumen to GammaCan, and specifically to the Company's mission of bringing VitiGam to the clinic, Dr. Spritz is a member of the Medical Advisory Board of Vitiligo Support International and a Council Member of PanAmerican Pigment Cell Society. "We are extremely pleased that Richard has joined our Scientific Advisory Board and are honored by his participation. Richard's work on the identification and cloning of genes involved in the pathogenesis vitiligo is groundbreaking and undoubtedly will lead to new insights into this and other immune-mediated disorders. We both recognized the connection between our respective research efforts, and the entire Team at GammaCan is exited to work with Richard as we develop VitiGam to treat stage III and IV melanoma," stated Patrick Schnegelsberg, CEO. Dr. Spritz is presently Director Human Medical Genetics Program and Professor of Pediatrics, Biochemistry and Molecular Genetics at the University of Colorado Health Science Center. Prior to his tenure at the University of Colorado, Dr. Spritz served as Assistant and Associate Professor of Medical Genetics and Pediatrics at the University of Wisconsin. Among his numerous accomplishments, Dr. Spritz sits on the Medical Advisory Board of Vitiligo Support International, is a member of The Council, PanAmerican Pigment Cell Society, Chaired a number of NIH Committees, and has for many years served on National Research Advisory Committees for the March of Dimes Birth Defects Foundation. He has been published over 170 peer-reviewed papers and receives ongoing research support from the NIH, specifically in the genetics of human pigmentation and autoimmune disorders. Richard Spritz holds an M.D. from Pennsylvania State University and was a Fellow in Human Genetics at the Yale University School of Medicine. "I am delighted to be associated with GammaCan, and look forward to contributing to the company's efforts, to develop VitiGam. I believe this has the potential to be an important therapeutic to help patients suffering from advanced melanoma," said Spritz. About VitiGam: VitiGam is GammaCan's second generation intravenous IgG-based product and a first-in-class anti-cancer immunotherapy. GammaCan plans on having VitiGam to enter phase I/II testing under a US IND in the near future after it recently held a pre-IND meeting with the FDA. VitiGam is being designed to target metastatic melanoma patients with Stage III and IV melanoma. VitiGam is an IgG product that is different from standard IgGs: It is manufactured from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that this "enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma activity in both in vitro and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to provide (1) anti-melanoma activity directed specifically against malignant melanoma cells and (2) non-specific anti-cancer activity - as is the case with IgG in general. About GammaCan: GammaCan is a biopharmaceutical company focused on clinical-phase development and commercialization. GammaCan's initial therapy under development is a first-in-class anti-cancer immunotherapy aimed at preventing metastasis (the spread of cancer to other parts of the body) of a variety of cancers. GammaCan's first generation product (GCAN101) is currently completing phase II - clinical trials. For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free 1-866-308-0396 (from North America). Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIg into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar.